Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment

20 Aug 2021

Abstract excerpt

Current systemic treatment options for patients with adrenocortical carcinomas (ACCs) are far from being satisfactory. DNA damage/repair mechanisms, which involve, e.g., ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia/Rad3-related (ATR) protein signaling or ribonucleotide reductase subunits M1/M2 (RRM1/RRM2)-encoded ribonucleotide reductase (RNR) activation, commonly contribute to drug resistance....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal and Paraganglionic Tumors
Share to Cancer, Hypoxia, and Metabolism
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34439352
DOI: 10.3390/cancers13164200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma TreatmentPMID 34439352Read ↗

Ribonucleotide Reductase Large Subunit ( RRM1 ) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical CancerSemantic proximity Read ↗

Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging OptionsSemantic proximity Read ↗

Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and PresentSemantic proximity Read ↗

Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.Semantic proximity Read ↗

Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral AgentsSemantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancerSemantic proximity Read ↗

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.Semantic proximity Read ↗

Molecular basis of adrenocortical carcinomas.Semantic proximity Read ↗

Inhibiting RRM2 to enhance the anticancer activity of chemotherapySemantic proximity Read ↗

MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cellsSemantic proximity Read ↗

The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.